A first-in-human study of MSB-2311
Phase of Trial: Phase I
Latest Information Update: 25 Oct 2017
At a glance
- Drugs MSB 2311 (Primary)
- Indications Cancer
- Focus Adverse reactions; First in man
- 25 Oct 2017 According to a MabSpace Biosciences media release, company filed an IND application to CFDA on September 12th, 2017 for MSB2311 and plans to file US IND in December 2017 and start an FIH trial in the US and subsequently in China in the first half of 2018.
- 07 Mar 2017 New trial record
- 23 Feb 2017 According to a MabSpace Biosciences media release, the company is planning to start this study later this year.